Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 52-Week High – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price hit a new 52-week high during trading on Friday . The company traded as high as $34.84 and last traded at $33.8450, with a volume of 84505 shares. The stock had previously closed at $33.00.

Wall Street Analysts Forecast Growth

CHGCY has been the topic of a number of recent analyst reports. UBS Group upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, Chugai Pharmaceutical has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Up 1.8%

The firm has a market cap of $110.61 billion, a PE ratio of 38.63 and a beta of 0.63. The stock has a 50 day moving average price of $28.29 and a two-hundred day moving average price of $25.44.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Thursday, January 29th. The company reported $0.25 EPS for the quarter. The company had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. As a group, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.